Page contentsKey factsDecisionKey facts Active Substance sumatriptannaproxen (sodium) Therapeutic area Neurology Decision number P/0208/2021 PIP number EMEA-002959-PIP01-21 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of migraine headaches Route(s) of administration Oral use Contact for public enquiries Orion CorporationE-mail: orionra@orionpharma.comTel: +358 982564248 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 10/05/2021DecisionP/0208/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for sumatriptan / naproxen (sodium) (EMEA-002959-PIP01-21)AdoptedReference Number: EMA/244109/2021 English (EN) (178.15 KB - PDF)First published: 15/02/2022ViewShare this page